Erik Cederfjäll, Ph.D.
Affiliations: | 2008-2014 | B.R.A.I.N.S. Unit | Lund University, Lund, Skåne län, Sweden |
2015-2017 | Molecules - Signaling - Development | Max Planck Institute of Neurobiology, Jupiter, FL, United States |
Area:
Parkinson's disease | Gene therapyGoogle:
"Erik Cederfjäll"Mean distance: 17.38 (cluster 11)
Parents
Sign in to add mentorDeniz Kirik | grad student | 2010-2014 | Lund University |
Ruediger Klein | post-doc | 2015-2017 | Max Planck Institute of Neurobiology |
BETA: Related publications
See more...
Publications
You can help our author matching system! If you notice any publications incorrectly attributed to this author, please sign in and mark matches as correct or incorrect. |
Del Toro D, Ruff T, Cederfjäll E, et al. (2017) Regulation of Cerebral Cortex Folding by Controlling Neuronal Migration via FLRT Adhesion Molecules. Cell. 169: 621-635.e16 |
Kirik D, Cederfjäll E, Halliday G, et al. (2016) Gene therapy for Parkinson's disease: Disease modification by GDNF family of ligands. Neurobiology of Disease |
Cederfjäll E, Broom L, Kirik D. (2015) Controlled Striatal DOPA Production From a Gene Delivery System in a Rodent Model of Parkinson's Disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 23: 896-906 |
Cederfjäll E, Nilsson N, Sahin G, et al. (2013) Continuous DOPA synthesis from a single AAV: dosing and efficacy in models of Parkinson's disease. Scientific Reports. 3: 2157 |
Cederfjäll E, Sahin G, Kirik D, et al. (2012) Design of a single AAV vector for coexpression of TH and GCH1 to establish continuous DOPA synthesis in a rat model of Parkinson's disease. Molecular Therapy : the Journal of the American Society of Gene Therapy. 20: 1315-26 |
Cederfjäll E, Sahin G, Kirik D. (2012) Key factors determining the efficacy of gene therapy for continuous DOPA delivery in the Parkinsonian brain. Neurobiology of Disease. 48: 222-7 |
Björklund T, Cederfjäll EA, Kirik D. (2010) Gene therapy for dopamine replacement. Progress in Brain Research. 184: 221-35 |
Björklund T, Carlsson T, Cederfjäll EA, et al. (2010) Optimized adeno-associated viral vector-mediated striatal DOPA delivery restores sensorimotor function and prevents dyskinesias in a model of advanced Parkinson's disease. Brain : a Journal of Neurology. 133: 496-511 |